Welcome to our dedicated page for NetraMark Holdings news (Ticker: AINMF), a resource for investors and traders seeking the latest updates and insights on NetraMark Holdings stock.
NetraMark Holdings Inc. (OTCQB: AINMF) generates news centered on the application of explainable artificial intelligence to pharmaceutical clinical trials. The company regularly reports on contracts with global pharmaceutical and biopharmaceutical companies, collaborations with research institutions, scientific publications, and regulatory-science interactions related to its NetraAI platform.
News updates often highlight new agreements in which NetraAI is applied to late-stage clinical studies, including Phase III trials in psychiatric indications. These announcements describe how NetraAI is used to identify responder and non-responder subgroups, analyze treatment and placebo-response patterns, and support interpretation of complex trial outcomes. The company also reports on expansions of existing relationships through master services agreements and the growth of its contract backlog for NetraAI services.
Another recurring theme in NetraMark’s news is its scientific and academic engagement. The company has announced acceptance of a peer-reviewed NetraAI study in npj Digital Medicine, presentations at CNS-focused clinical trial and neuropsychopharmacology conferences, and research collaborations in areas such as major depressive disorder, schizophrenia, and glioblastoma. These items describe how NetraAI is deployed within secure research environments to analyze clinical, genetic, epigenetic, and proteomic datasets and to uncover explainable patient subpopulations.
Regulatory-science news includes coverage of NetraMark’s Critical Path Innovation Meeting with the U.S. Food and Drug Administration, where the scientific aspects of NetraAI’s enrichment methodology were discussed. Financing news, such as private placement offerings, provides context on how the company plans to fund advancement and commercialization of NetraAI and support ongoing and prospective biopharmaceutical engagements.
Investors and observers who follow AINMF news can therefore expect updates on commercial contracts, research collaborations, peer-reviewed publications, regulatory-science interactions, and capital-raising activities, all tied to the development and deployment of NetraAI in pharmaceutical clinical development.
NetraMark Holdings (OTCQB:AINMF) presented groundbreaking AI research at the ISCTM conference, showcasing advancements in clinical trial analytics for major depressive disorder (MDD) and schizophrenia.
The company's NetraAI Sub-Insight Learning demonstrated significant improvements in MDD clinical trials, achieving:
- 28% increase in model accuracy
- 31% improvement in sensitivity
- 51% increase in specificity
In schizophrenia research, NetraAI identified distinct patient subgroups responding differently to treatments: patients with moderate-severe symptoms responded better to olanzapine, while those with moderate negative symptoms showed improved response to perphenazine.
NetraMark Holdings Inc. (CSE: AIAI) (OTCQB: AINMF), a leader in AI-driven clinical trial analytics, will participate in the 2024 Cantech Letter Conference on October 9, 2024, in Toronto. CEO George Achilleos will deliver a corporate presentation at 4:30 pm in Track 2 and conduct 1-on-1 investor meetings.
The presentation will highlight NetraMark's AI technology for optimizing clinical trials, focusing on:
- Identifying subpopulations driving drug response, placebo response, and adverse events
- Informing trial strategies to improve success likelihood
- Proprietary commercial-ready platform
- Collaborations with NIMH, Boston University, and Ontario Brain Institute
- Market entry strategy in CNS and Oncology
- Established client base and sales pipeline
- Favorable financial drivers with 90%+ gross margin
This event aims to strengthen NetraMark's capital market connections and increase investor visibility.
Summary not available.